Insilico Medicine Company
Insilico Medicine is dedicated to develop high-performance AI platform for drug development to treat cancer and age-related diseases
Investors
Technology:
AI for Longevity
Industry:
Artificial Intelligence, Biotechnology, Genetics, Pharmaceutical
Headquarters:
Hong Kong
Founded Date:
2014-01-01
Employees Number:
11-50
Funding Status:
Early Stage Venture
Investors Number:
16
Total Funding:
51300000
Estimated Revenue:
Less than $1M
Last Funding Date:
2020-04-20
Last Funding Type:
Series B
Register and Claim Ownership